FAQs

We are aiming to launch the device called ‘Neupulse’ in 2026 following regulatory approval ensuring its compliance to all relevant safety, quality and regulatory requirements.

The device and associated accessories will be available to purchase via our website in each country / region once we have received regulatory approval there.

The device delivers a pattern of electrical pulses to the underside of the wrist which can be activated on demand. The stimulation interacts with the nerves and parts of the brain which cause tics. Neupulse provides relief and a way to manage the symptoms and discomfort associated with tics.

Our research has been conducted on individuals from the age of 12 years old and over and the data shows the stimulation is effective however it may not be suitable for everyone and is contraindicated for some medical conditions.

The UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome run by Neupulse, Nottinghamshire Healthcare NHS Foundation Trust and the University of Nottingham showed that people who received active stimulation experienced a significant reduction in the severity and frequency of their tics. On average they saw a reduction in tic frequency of more than 25% while they received stimulation.

After using the device for 4 weeks, people who received active stimulation experienced a reduction in their tic severity of more than 35%. In total 59% of the people who received active stimulation experienced a reduction in tic severity of at least 25% compared to baseline.

Residents in the United Kingdom can sign up to our Research Mailing List to express their interest in participating in our research.

Please note that there is no guarantee of being recruited to participate in our research.

We currently only have ethics approval to conduct research on participants who reside in the UK. This may change in the future as we expand so please keep an eye on our website for updates.